Moleculin Biotech Inc (MBRX) Faces Mixed Analyst Ratings Amid Clinical Advances
In a recent analytical spotlight, Moleculin Biotech Inc (NASDAQ:MBRX), a trailblazer in clinical-stage pharmaceutical development, has garnered attention from financial analysts, steering towards a complex market trajectory. StockNews.com initiated coverage on the company, bestowing a “sell” rating, while contrasting positions emerged from HC Wainwright and Maxim Group, both advocating a “buy” stance albeit with revised price targets.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
